procarbazine hydrochloride

Phase 3Small molecule

Radiation Therapy Oncology Group

procarbazine hydrochloride is one of 284 small molecule programs targeting Glioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

283

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaUnknown

Primitive Neuroectodermal TumorActive, not recruiting

Central Nervous System LymphomaActive, not recruiting

Central Nervous System NeoplasmActive, not recruiting

LymphomaActive, not recruiting

Anaplastic AstrocytomaUnknown

Anaplastic OligodendrogliomaActive, not recruiting

Malignant GliomaActive, not recruiting

OligodendrogliomaUnknown

Bone Marrow TransplantationActive, not recruiting

GliomaPreclinical

Unknown

Primitive Neuroectodermal TumorPhase 2

Active, not recruiting

Central Nervous System LymphomaPhase 2

Active, not recruiting

Central Nervous System NeoplasmPhase 3

Active, not recruiting

LymphomaPhase 3

Active, not recruiting

Anaplastic AstrocytomaPreclinical

Unknown

Anaplastic OligodendrogliomaPhase 3

Active, not recruiting

Malignant GliomaPhase 2

Active, not recruiting

OligodendrogliomaPreclinical

Unknown

Bone Marrow TransplantationPhase 2

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

procarbazine hydrochloride

Radiation Therapy Oncology Group

Phase 3

17 2

Oncaspar

SServier

Preclinical

15 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 4

Tafasitamab

Incyte

Preclinical

7 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 3Recruiting

Hodgkin Lymphoma

NCT05675410

Clinical

Trials by Indication[1]

Lymphoma17 trials

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00822120·371 enrolled

Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT01775475·7 enrolled

Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma

Completed·UUniversity College, London·Phase 2·NCT00666484·47 enrolled

Show 14 more trials

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01132807·164 enrolled

Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 2·NCT00025064·260 enrolled

Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

Completed·UUniversity College, London·Phase 3·NCT00678327·1,202 enrolled

Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas

Terminated·—·Phase 2·NCT00003113·6 enrolled

Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma

Completed·—·Phase 2·NCT00049439·54 enrolled

Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma

Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00379041·1,158 enrolled

Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

Completed·CChristine Mauz-Körholz·Phase 3·NCT00433459·2,134 enrolled

Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

Unknown status·CChildren's Cancer and Leukaemia Group·N/A·NCT00416377·353 enrolled

Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT00074191·1 enrolled

A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years

Completed·NNewcastle-upon-Tyne Hospitals NHS Trust·Phase 2·NCT00079105·175 enrolled

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00049595·552 enrolled

Combination Chemotherapy and/or Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma

Unknown status·CChildren's Cancer and Leukaemia Group·N/A·NCT00417014·358 enrolled

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma

Completed·CChristine Mauz-Körholz·Phase 2·NCT00416832·648 enrolled

Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00574496·25 enrolled

Hodgkin's Disease4 trials

Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease

Completed·MMedical Research Council·Phase 3·NCT00003421·800 enrolled

RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease

Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002462·615 enrolled

Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease

Completed·—·Phase 2·NCT00003114·5 enrolled

Show 1 more trial

Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease

Completed·CChildren's Oncology Group·Phase 2·NCT00004010·99 enrolled

Glioma3 trials

Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas

Unknown status·CColorado Health Foundation·Phase 3·NCT00003788·270 enrolled

Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2/3·NCT00003375·370 enrolled

Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00002806·43 enrolled

Malignant Glioma3 trials

Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma

Completed·IInstitute of Cancer Research, United Kingdom·Phase 3·NCT00052455·500 enrolled

Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas

Withdrawn·MM.D. Anderson Cancer Center·Phase 3·NCT00003564

Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma

Completed·WWake Forest University Health Sciences·Phase 2·NCT00079092·18 enrolled

Chemotherapy2 trials

Combination Chemotherapy in Treating Children With Progressive Brain Tumors

Completed·CChildren's Oncology Group·Phase 3·NCT00002944·428 enrolled

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

Completed·IIndiana University·Phase 1·NCT00005796·10 enrolled

8 more indications

Anaplastic Oligodendroglioma2 trials

Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002840·350 enrolled

Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00002569·299 enrolled

Immunotherapy1 trial

Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL

Withdrawn·NNorthwestern University·Phase 1·NCT00734773

Brain Tumor1 trial

Procarbazine in Treating Patients With Recurrent Brain Tumor

Completed·NNew Approaches to Brain Tumor Therapy Consortium·Phase 1/2·NCT00004004

Glioblastoma Multiforme1 trial

SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme

Completed· Pfizer logo

Pfizer·Phase 3·NCT00003293

Bone Marrow Transplantation1 trial

Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003101·60 enrolled

Primitive Neuroectodermal Tumor1 trial

Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00002463·4 enrolled

Central Nervous System Lymphoma1 trial

Chemotherapy, Filgrastim, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Withdrawn·—·Phase 2·NCT00003929

Hodgkin Lymphoma1 trial

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT05675410·1,875 enrolled

Sources

References

[1]
ClinicalTrials.gov — 38 trial records for procarbazine hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — procarbazine hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for procarbazine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Radiation Therapy Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Radiation Therapy Oncology Group

procarbazine hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Lymphoma17 trials

Hodgkin's Disease4 trials

Glioma3 trials

Malignant Glioma3 trials

Chemotherapy2 trials

Anaplastic Oligodendroglioma2 trials

Immunotherapy1 trial

Brain Tumor1 trial

Glioblastoma Multiforme1 trial

Bone Marrow Transplantation1 trial

Primitive Neuroectodermal Tumor1 trial

Central Nervous System Lymphoma1 trial

Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News